[[File:Rational harm assessment of drugs radar plot.svg|thumb|Addiction experts in psychiatry, chemistry, pharmacology, [[forensic science]], epidemiology, and the police and legal services engaged in [[Delphi method|delphic analysis]] regarding 20 popular recreational drugs. Methylphenidate was ranked 13th in dependence, 12th in physical harm, and 18th in social harm.<ref>{{cite journal|last1=Nutt|first1=D|last2=King|first2=LA|last3=Saulsbury|first3=W|last4=Blakemore|first4=C|title=Development of a rational scale to assess the harm of drugs of potential misuse.|journal=Lancet|date=24 March 2007|volume=369|issue=9566|pages=1047–53|pmid=17382831|doi=10.1016/S0140-6736(07)60464-4}}</ref>]]

 
<onlyinclude>{{#ifeq:{{{transcludesection|Adverse effects}}}|Adverse effects|

 
Methylphenidate is generally well tolerated.<ref>{{cite journal|last1=Didoni|first1=A|last2=Sequi|first2=M|last3=Panei|first3=P|last4=Bonati|first4=M|last5=Lombardy ADHD Registry|first5=Group|title=One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder.|journal=European journal of clinical pharmacology|date=October 2011|volume=67|issue=10|pages=1061–7|doi=10.1007/s00228-011-1050-3|pmid=21538145}}<br />• {{cite web|title=Ritalin Side Effects |url=http://www.drugs.com/sfx/ritalin-side-effects.html |accessdate=22 June 2015 }}<br />• {{cite web|title=Biphentin product monograph |url=http://www.purdue.ca/files/2012-11-23%20Biphentin%20PM_ENG%20Final.pdf |publisher=Purdue Pharma |accessdate=22 June 2015 |deadurl=yes |archiveurl=https://web.archive.org/web/20150622173949/http://www.purdue.ca/files/2012-11-23%20Biphentin%20PM_ENG%20Final.pdf |archivedate=22 June 2015 |df= }}<br />• {{cite journal|last1=Huss|first1=M|last2=Ginsberg|first2=Y|last3=Tvedten|first3=T|last4=Arngrim|first4=T|last5=Philipsen|first5=A|last6=Carter|first6=K|last7=Chen|first7=CW|last8=Kumar|first8=V|title=Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.|journal=Advances in therapy|date=January 2014|volume=31|issue=1|pages=44–65|pmid=24371021|doi=10.1007/s12325-013-0085-5|pmc=3905180}}</ref><ref name="concerta_monograph">{{cite web|title=Concerta product monograph|url=https://www.janssenmd.com/pdf/concerta/CONCERTA_PI.pdf|publisher=Janssen Pharmaceuticals|accessdate=4 December 2016}}</ref> The most commonly observed adverse effects with a frequency greater than [[placebo]] include [[Anorexia (symptom)|appetite loss]], [[Xerostomia|dry mouth]], [[Anxiety|anxiety/nervousness]], [[nausea]], and [[insomnia]]. [[Gastrointestinal]] adverse effects may include [[abdominal pain]] and [[weight loss]]. Nervous system adverse effects may include [[akathisia]] (agitation/restlessness), [[Anger|irritability]], [[dyskinesia]] (tics), [[lethargy]] (drowsiness/fatigue), and [[dizziness]]. [[Cardiac]] adverse effects may include [[palpitations]], changes in [[blood pressure]] and [[pulse|heart rate]] (typically mild), [[tachycardia]] (rapid resting heart rate), and [[Raynaud's phenomenon]] (reduced blood flow to the hands and feet).<ref name = "Ritalin Rx info" /> [[Ophthalmologic]] adverse effects may include [[blurred vision]] and dry eyes, with less frequent reports of [[diplopia]] and [[mydriasis]].<ref>{{cite journal | author = Jaanus SD | title = Ocular side-effects of selected systemic drugs | journal = Optom Clin | volume = 2 | issue = 4 | pages = 73–96 | year = 1992 | pmid = 1363080 }}</ref> Other adverse effects may include [[Depression (mood)|depression]], [[Pseudobulbar affect|emotional lability]], [[confusion]], and [[bruxism]]. [[Hyperhidrosis]] (increased sweating) is common. [[Angina|Chest pain]] is rarely observed.<ref>{{cite journal|author=Stein|display-authors= etal|title=Sleep disturbances in children with Attention-Deficit/Hyperactivity Disorder a comparative study with healthy siblings|journal=Journal of Learning Disabilities|volume=31|issue=6|pages= 572–578|year=1998}}</ref>

 


 
There is some evidence of mild reductions in growth rate with prolonged treatment in children, but no causal relationship has been established and reductions do not appear to persist long-term.<ref name="pmid23294014">{{cite journal|last1=Cortese|first1=S|last2=Holtmann|first2=M|last3=Banaschewski|first3=T|last4=Buitelaar|first4=J|last5=Coghill|first5=D|last6=Danckaerts|first6=M|last7=Dittmann|first7=RW|last8=Graham|first8=J|last9=Taylor|first9=E|last10=Sergeant|first10=J|last11=European ADHD Guidelines|first11=Group|title=Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.|journal=Journal of child psychology and psychiatry, and allied disciplines|date=March 2013|volume=54|issue=3|pages=227–46|pmid=23294014|doi=10.1111/jcpp.12036}}</ref> [[Hypersensitivity]] (including [[skin rash]], [[urticaria]], and [[fever]]) is sometimes reported. The [[Daytrana]] patch has a much higher rate of [[dermal]] reactions than oral methylphenidate.<ref>{{cite journal|last1=Findling|first1=RL|last2=Dinh|first2=S|title=Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS).|journal=CNS Drugs|date=March 2014|volume=28|issue=3|pages=217–28|pmid=24532028|doi=10.1007/s40263-014-0141-y|pmc=3933749}}</ref>

 


 
Methylphenidate can worsen [[psychosis]] in psychotic patients, and in very rare cases it has been associated with the emergence of new psychotic symptoms.<ref name="pmid20571380">{{cite journal |vauthors=Kraemer M, Uekermann J, Wiltfang J, Kis B | title = Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature | journal = Clin Neuropharmacol | volume = 33 | issue = 4 | pages = 204–6 | date = July 2010 | pmid = 20571380 | doi = 10.1097/WNF.0b013e3181e29174 }}</ref> It should be used with extreme caution in patients with [[bipolar disorder]] due to the potential induction of [[mania]] or [[hypomania]].<ref>{{cite journal|last1=Wingo|first1=AP|last2=Ghaemi|first2=SN|title=Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients.|journal=Psychopharmacology bulletin|date=2008|volume=41|issue=4|pages=37–47|pmid=19015628}}</ref> There have been very rare reports of [[suicidal ideation]], but evidence does not support a link.<ref name="pmid23294014"/> [[Logorrhea (psychology)|Logorrhea]] is occasionally reported. [[Libido]] disorders, [[disorientation]], and [[hallucinations]] are very rarely reported. [[Priapism]] is a very rare adverse event that can be potentially serious.<ref name=FDA>{{cite web|url=http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm378876.htm|title=Methylphenidate ADHD Medications: Drug Safety Communication – Risk of Long-lasting Erections|work=[[U.S. Food and Drug Administration]]|date=17 December 2013|accessdate=17 December 2013}}</ref>

 


 
USFDA-commissioned studies from 2011 indicate that in children, young adults, and adults there is no association between serious adverse [[cardiovascular disease|cardiovascular events]] ([[sudden cardiac death|sudden death]], [[myocardial infarction|heart attack]], and [[stroke]]) and the medical use of methylphenidate or other ADHD stimulants.<ref>{{cite web | title=FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults | date=20 December 2011 | url=http://www.fda.gov/Drugs/DrugSafety/ucm277770.htm | work=United States Food and Drug Administration | accessdate=4 November 2013}}<br />• {{cite journal |vauthors=Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA | title = ADHD drugs and serious cardiovascular events in children and young adults | journal = N. Engl. J. Med. | volume = 365 | issue = 20 | pages = 1896–1904 |date=November 2011 | pmid = 22043968 | doi = 10.1056/NEJMoa1110212 | pmc=4943074}}<br />• {{cite web | title=FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults | date=15 December 2011 | url=http://www.fda.gov/Drugs/DrugSafety/ucm279858.htm | work=United States Food and Drug Administration | accessdate=4 November 2013}}<br />• {{cite journal |vauthors=Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV | title = ADHD medications and risk of serious cardiovascular events in young and middle-aged adults |date=December 2011 | journal = JAMA | volume = 306 | issue = 24 | pages = 2673–2683 | pmid = 22161946 | pmc = 3350308 | doi = 10.1001/jama.2011.1830 }}</ref>

 


 
Because some adverse effects may only emerge during chronic use of methylphenidate, a constant watch for adverse effects is recommended.<ref>{{cite journal | author = Gordon N | title = Attention deficit hyperactivity disorder: possible causes and treatment | journal = Int. J. Clin. Pract. | volume = 53 | issue = 7 | pages = 524–8 | year = 1999 | pmid = 10692738 }}</ref>

 
}}</onlyinclude>

 

